Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; and PRT-K4 that is in preclinical stage for solid tumors. Prelude Therapeutics Incorporated was incorporated in 2016 and is headquartered in Wilmington, Delaware.
IPO Year: 2020
Exchange: NASDAQ
Website: preludetx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/19/2024 | $5.00 | Neutral → Buy | H.C. Wainwright |
| 6/20/2024 | $3.00 | Equal Weight → Underweight | Barclays |
| 3/13/2024 | $7.00 | Mkt Outperform | JMP Securities |
| 2/20/2024 | $5.00 | Buy → Neutral | H.C. Wainwright |
| 12/19/2023 | $10.00 → $4.00 | Equal-Weight → Underweight | Morgan Stanley |
| 11/21/2022 | $8.00 → $6.00 | Neutral → Underperform | BofA Securities |
| 9/9/2022 | $19.00 → $11.00 | Overweight → Equal-Weight | Morgan Stanley |
| 7/29/2022 | $9.00 | Buy | Jefferies |
| 3/15/2022 | $50.00 → $10.00 | Buy → Neutral | BofA Securities |
| 2/28/2022 | $20.00 → $12.00 | Overweight → Equal-Weight | Barclays |
Presented interim data from the ongoing Phase 1 dose escalation study of PRT3789, its first-in-class IV SMARCA2 degrader, demonstrating clinical proof of concept Initiated a Phase 1 trial for PRT7732, its first-in-class oral SMARCA2 degrader in patients with SMARCA4-mutated cancers Presented first preclinical data from its next generation degrader antibody conjugate (Precision ADC) platform Interim phase 1 clinical data with potentially best-in-class CDK9 inhibitor, PRT2527, in hematological malignancies to be presented at the American Society of Hematology Annual Meeting in December 2024 Current cash runway into 2026 with $153.6 million in cash, cash equivalents and marketable securiti
– Interim data from ongoing trial of PRT3789 showed additional clinical activity at higher doses in patients with non-small cell lung cancer (NSCLC) – First safety data presented from combination study of PRT3789 and docetaxel demonstrated an acceptable safety profile – First preclinical proof-of-concept data presented from precision antibody drug conjugate program deploying a novel SMARCA2/4 dual degrader payload WILMINGTON, Del., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD) ("Prelude" or the "Company"), a clinical-stage precision oncology company, today announced the presentation of additional data from its ongoing Phase 1 open-label, dose-escalati
WILMINGTON, Del., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD) ("Prelude" or the "Company"), a clinical-stage precision oncology company, today announced the publication of three abstracts regarding its SMARCA Degrader Programs at the 36th EORTC-NCI-AACR Symposium taking place in Barcelona, Spain October 23-25, 2024. The abstracts can be found at Conference (eortc.org). "We are delighted to have this opportunity to share additional information from our SMARCA degrader programs to the scientific and medical communities as we continue to progress both the clinical and preclinical development of these novel first-in-class approaches for patients with high
- Encouraging signs of anti-tumor activity including objective responses observed in patients with SMARCA4-mutated non-small cell lung cancer (NSCLC) and esophageal cancer in early PRT3789 monotherapy dose escalation - At doses studied to date, PRT3789 was generally well-tolerated with no dose-limiting toxicities or study drug-related serious adverse events - Company to host investor conference call and webcast on Friday, September 13, 2024 at 12:00 PM EST WILMINGTON, Del., Sept. 13, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD), a clinical-stage precision oncology company, today announced the first interim clinical
PRT3789, a novel, highly-selective SMARCA2 degrader in patients with advanced solid tumors with a SMARCA4 mutation oral session presentation: September 13, 2024, 4:00 PM CEST (10:00 AM EST) Prelude will host an investor webcast on September 13, 2024, 6:00 PM CEST, (12:00 PM EST) WILMINGTON, Del., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD) ("Prelude" or the "Company"), a clinical-stage precision oncology company, today announced the publication of an abstract regarding PRT3789 at the European Society of Medical Oncology (ESMO) Congress 2024 taking place in Barcelona, Spain September 13-17, 2024. The abstract can be found on the ESMO 2024 website
Interim Phase 1 data for its first-in-class, highly selective IV SMARCA2 degrader, PRT3789, selected for an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024 in September Received investigational new drug (IND) authorization for PRT7732, its first-in-class oral SMARCA2 degrader, from the U.S. Food and Drug Administration (FDA) Announced clinical collaboration with Merck to evaluate PRT3789 in combination with Merck's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with SMARCA4-mutated cancers Potentially best-in-class CDK9 inhibitor, PRT2527, remains on track to report interim Phase 1 data in Q4 2024 Current cash runway into 2026 with $1
Combining a first-in-class, highly selective SMARCA2 degrader with an anti-PD-1 therapy may potentially enhance the anti-tumor activity of either agent because of the complementary nature of the two mechanisms. Prelude will sponsor the clinical trial and Merck will provide KEYTRUDA. WILMINGTON, Del., July 09, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD) ("Prelude" or the "Company"), a clinical-stage precision oncology company, today announced that it has entered into a clinical trial collaboration and supply agreement (the "Agreement") with Merck (known as MSD outside of the US and Canada). Under the terms of the Agreement, the Phase 2 clinical study will eval
WILMINGTON, Del., June 03, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in two upcoming healthcare conferences in June. Jefferies Global Healthcare Conference 2024:On Thursday, June 6th, at 1:30 p.m. ET, Kris Vaddi, Ph.D., Chief Executive Officer of Prelude will participate in a fireside chat. A live webcast of the fireside chat can be accessed here. Goldman Sachs 45th Annual Global Healthcare Conference:On Wednesday, June 12th, at 10:40 a.m. ET, Dr. Vaddi will provide a corporate presentation. The live webcast of the presentation can be accessed here. For more inf
WILMINGTON, Del., May 09, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (NASDAQ:PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Citizens JMP Life Sciences Conference, taking place in New York City on May 13 and 14. On Tuesday, May 14, at 1:00 p.m. ET, Kris Vaddi, Ph.D., Chief Executive Officer of Prelude, and Jane Huang, M.D., President and Chief Medical Officer, will participate in a fireside chat. A live webcast of the fireside chat can be accessed here and on the Company's website under Events and Presentations. The recording will be archived and available on the Company's website for 90 days. About P
First-in-class IV SMARCA2 degrader, PRT3789 and potentially best-in-class CDK9 inhibitor, PRT2527 remain on track to generate initial proof-of-concept data in 2024 New preclinical data presented at AACR 2024 included first characterization of PRT7732, a highly-selective, orally bioavailable SMARCA2 degrader Operational leadership capabilities further strengthened by recent hires Chief Business Officer Sean Brusky and Senior Vice President, Investor Relations Robert Doody Current cash runway into 2026 with $201.9 million in cash, cash equivalents and marketable securities as of March 31, 2024 WILMINGTON, Del., May 07, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ
10-Q - Prelude Therapeutics Inc (0001678660) (Filer)
8-K - Prelude Therapeutics Inc (0001678660) (Filer)
8-K - Prelude Therapeutics Inc (0001678660) (Filer)
8-K - Prelude Therapeutics Inc (0001678660) (Filer)
8-K - Prelude Therapeutics Inc (0001678660) (Filer)
10-Q - Prelude Therapeutics Inc (0001678660) (Filer)
8-K - Prelude Therapeutics Inc (0001678660) (Filer)
8-K - Prelude Therapeutics Inc (0001678660) (Filer)
8-K - Prelude Therapeutics Inc (0001678660) (Filer)
EFFECT - Prelude Therapeutics Inc (0001678660) (Filer)
- Encouraging signs of anti-tumor activity including objective responses observed in patients with SMARCA4-mutated non-small cell lung cancer (NSCLC) and esophageal cancer in early PRT3789 monotherapy dose escalation - At doses studied to date, PRT3789 was generally well-tolerated with no dose-limiting toxicities or study drug-related serious adverse events - Company to host investor conference call and webcast on Friday, September 13, 2024 at 12:00 PM EST WILMINGTON, Del., Sept. 13, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD), a clinical-stage precision oncology company, today announced the first interim clinical
PRT3789, a novel, highly-selective SMARCA2 degrader in patients with advanced solid tumors with a SMARCA4 mutation oral session presentation: September 13, 2024, 4:00 PM CEST (10:00 AM EST) Prelude will host an investor webcast on September 13, 2024, 6:00 PM CEST, (12:00 PM EST) WILMINGTON, Del., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD) ("Prelude" or the "Company"), a clinical-stage precision oncology company, today announced the publication of an abstract regarding PRT3789 at the European Society of Medical Oncology (ESMO) Congress 2024 taking place in Barcelona, Spain September 13-17, 2024. The abstract can be found on the ESMO 2024 website
PRT543 and PRT811 Demonstrate Favorable Safety Profile, Tolerability and Evidence of Preliminary Clinical Activity in Phase 1 Dose Escalation in Unselected Patients Phase 1 Dose Expansion Ongoing in Biomarker-Selected Solid Tumor and Hematologic Malignancy Expansion Cohorts for PRT543; Dose Expansion Portion of Phase 1 Trial of PRT811 to Commence 4Q21 with Data Readouts Anticipated for Both Programs in 2022 PRT2527 IND Cleared by FDA; Phase 1 Clinical Trial Evaluating IV Monotherapy in Patients with Selected Solid Tumors Anticipated to Begin by Year-End Strong Cash, Cash Equivalents and Marketable Securities Position of $320 Million to Support Clinical and Discovery Pipeline Advance
- Data from Dose Escalation Portion of Phase 1 Trials of Lead Oral PRMT5 Inhibitors PRT543 and PRT811 to be Presented in 4Q21 – - Enrollment Ongoing in Multiple Expansion Cohorts in Phase 1 Trial of PRT543; Dose Expansion Portion of Phase 1 Trial of PRT811 Expected to Commence in 3Q21 – - Dose Escalation Portion of Phase 1 Trials of Oral and IV Formulations of MCL1 Inhibitor PRT1419 Ongoing – -Strong Cash Position of $343 Million to Support Clinical and Discovery Pipeline Advancement – WILMINGTON, Del., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (NASDAQ:PRLD), a clinical-stage precision oncology company, today announced its financial results for the s
- Enrollment Now Underway in Multiple Solid Tumor and Hematologic Malignancy Expansion Cohorts in Phase 1 Trial of Oral PRMT5 Inhibitor PRT543 - - Initial Clinical Data Readouts for Lead Oral PRMT5 Inhibitors PRT543 and PRT811 Expected in 2H21 - - Dose Escalation Ongoing in Phase 1 Trial of Oral MCL1 Inhibitor PRT1419, with Dose Expansion Cohorts on Track to be Added in 2H21 - WILMINGTON, Del., May 11, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (NASDAQ:PRLD), a clinical-stage precision oncology company, today announced its financial results for the first quarter ended March 31, 2021 and provided an update on recent clinical and development pipeline progress. "With sever
SC 13G/A - Prelude Therapeutics Inc (0001678660) (Subject)
SC 13G/A - Prelude Therapeutics Inc (0001678660) (Subject)
SC 13G/A - Prelude Therapeutics Inc (0001678660) (Subject)
SC 13G/A - Prelude Therapeutics Inc (0001678660) (Subject)
SC 13D/A - Prelude Therapeutics Inc (0001678660) (Subject)
SC 13G - Prelude Therapeutics Inc (0001678660) (Subject)
SC 13D/A - Prelude Therapeutics Inc (0001678660) (Subject)
SC 13D/A - Prelude Therapeutics Inc (0001678660) (Subject)
SC 13G - Prelude Therapeutics Inc (0001678660) (Subject)
SC 13G/A - Prelude Therapeutics Inc (0001678660) (Subject)
4 - Prelude Therapeutics Inc (0001678660) (Issuer)
4 - Prelude Therapeutics Inc (0001678660) (Issuer)
4 - Prelude Therapeutics Inc (0001678660) (Issuer)
4 - Prelude Therapeutics Inc (0001678660) (Issuer)
4 - Prelude Therapeutics Inc (0001678660) (Issuer)
4 - Prelude Therapeutics Inc (0001678660) (Issuer)
4 - Prelude Therapeutics Inc (0001678660) (Issuer)
4 - Prelude Therapeutics Inc (0001678660) (Issuer)
4 - Prelude Therapeutics Inc (0001678660) (Issuer)
4 - Prelude Therapeutics Inc (0001678660) (Issuer)
Combining a first-in-class, highly selective SMARCA2 degrader with an anti-PD-1 therapy may potentially enhance the anti-tumor activity of either agent because of the complementary nature of the two mechanisms. Prelude will sponsor the clinical trial and Merck will provide KEYTRUDA.
-SEC Filing
JMP Securities analyst Reni Benjamin initiates coverage on Prelude Therapeutics (NASDAQ:PRLD) with a Market Outperform rating and announces Price Target of $7.
HC Wainwright & Co. analyst Robert Burns downgrades Prelude Therapeutics (NASDAQ:PRLD) from Buy to Neutral and announces $5 price target.
Gainers OneMedNet (NASDAQ:ONMD) shares rose 91.2% to $1.44 during Friday's regular session. The market value of their outstanding shares is at $46.4 million. Applied Therapeutics (NASDAQ:APLT) stock increased by 28.53% to $4.82. The market value of their outstanding shares is at $372.2 million. Modular Medical (NASDAQ:MODD) stock moved upwards by 24.58% to $1.56. The company's market cap stands at $34.2 million. As per the press release, Q3 earnings came out 3 days ago. Prelude Therapeutics (NASDAQ:PRLD) shares moved upwards by 23.27% to $4.29. The company's market cap stands at $235.2 million. Ocugen (NASDAQ:OCGN) shares rose 21.98% to $0.91. The company's market cap stands at $233.4 m
First-in-class IV SMARCA2 degrader and potentially best-in-class CDK9 inhibitor on track to generate potential proof-of-concept data in 2024 Highly selective oral SMARCA2 degrader PRT7732 IND expected to be filed in first half and enter Phase 1 clinical trial in second half of 2024Recently established partnership with AbCellera to jointly discover, develop, and commercialize a portfolio of next generation precision ADCsCurrent cash runway into 2026 with $232.9 million in cash, cash equivalents and marketable securities as of December 31, 2023WILMINGTON, Del., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD), a clinical-stage precision oncology company, today
Morgan Stanley downgraded its rating of Prelude Therapeutics (NASDAQ:PRLD) to Underweight with a price target of $4.00, changing its price target from $10.00 to $4.00. Shares of Prelude Therapeutics are trading up 0.0% over the last 24 hours, at $4.37 per share. A move to $4.00 would account for a 8.47% decrease from the current share price. About Prelude Therapeutics Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet need. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective
Morgan Stanley analyst Jeffrey Hung downgrades Prelude Therapeutics (NASDAQ:PRLD) from Equal-Weight to Underweight and lowers the price target from $10 to $4.
On December 11, 2023, Prelude Therapeutics Incorporated, a Delaware corporation (the "Company"), entered into a securities purchase agreement (the "Securities Purchase Agreement") with certain institutional accredited investors (the "Purchasers"), pursuant to which the Company agreed to issue and sell to the Purchasers in a private placement pre-funded warrants (the "Pre-Funded Warrants") to purchase up to 7,936,759 shares of the Company's voting common stock, par value $0.0001 per share (the "Common Stock"), at a price of $3.1499 per warrant with an exercise price of $0.0001 per share (the "Offering").Each Pre-Funded Warrant is immediately exercisable and will not expire. Under the terms of
H.C. Wainwright upgraded Prelude Therapeutics from Neutral to Buy and set a new price target of $5.00
Barclays downgraded Prelude Therapeutics from Equal Weight to Underweight and set a new price target of $3.00
JMP Securities initiated coverage of Prelude Therapeutics with a rating of Mkt Outperform and set a new price target of $7.00
H.C. Wainwright downgraded Prelude Therapeutics from Buy to Neutral and set a new price target of $5.00
Morgan Stanley downgraded Prelude Therapeutics from Equal-Weight to Underweight and set a new price target of $4.00 from $10.00 previously
BofA Securities downgraded Prelude Therapeutics from Neutral to Underperform and set a new price target of $6.00 from $8.00 previously
Morgan Stanley downgraded Prelude Therapeutics from Overweight to Equal-Weight and set a new price target of $11.00 from $19.00 previously
Jefferies initiated coverage of Prelude Therapeutics with a rating of Buy and set a new price target of $9.00
BofA Securities downgraded Prelude Therapeutics from Buy to Neutral and set a new price target of $10.00 from $50.00 previously
Barclays downgraded Prelude Therapeutics from Overweight to Equal-Weight and set a new price target of $12.00 from $20.00 previously
Prelude remains on track for clinical data readouts and next steps for the PRMT5 program, MCL1 inhibitor PRT1419, and CDK9 inhibitor PRT2527 in 2H2022 Strong cash and cash equivalents of $266.2 million as of March 31, 2022, expected to fund operations into 2H2024 WILMINGTON, Del., May 10, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated ("Prelude") (NASDAQ:PRLD), a clinical-stage precision oncology company, today reported financial results for the first quarter ended March 31, 2022, and provided an update on recent clinical and development pipeline progress. "Prelude continues to make great progress in discovering and advancing a diverse pipeline of differentiated small molecu
Significant progress achieved in 2021: Pipeline now includes six internally discovered small molecule compounds targeting clinically validated pathways in cancers with underserved patients Objectives for 2022: Focused on demonstrating proof-of-concept clinical data for lead pipeline compounds and continued advancement of Prelude's diverse precision oncology pipeline Cash runway guidance extended to 2H/2024 WILMINGTON, Del., March 16, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD), a clinical-stage precision oncology company, today reported its financial results for the fiscal year ended December 31, 2021. "With Prelude's core competencies in cancer biology an
WILMINGTON, Del., March 09, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD) a clinical-stage precision oncology company, today announced that Jane Huang, M.D., has been appointed to the newly created position of President and Chief Medical Officer, effective on April 4, 2022. Dr. Huang is currently Chief Medical Officer, Hematology, at BeiGene, Ltd., a global, science-driven biotechnology company developing oral small molecules and monoclonal antibodies for cancer. "We are pleased to announce that Dr. Huang will be joining Prelude. Jane's deep experience in oncology drug development and her strategic leadership throughout the lifecycle of multiple products resulti
WILMINGTON, Del., July 19, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (NASDAQ:PRLD), a clinical-stage precision oncology company, today announced the appointment of Martin Babler to its Board of Directors. Mr. Babler brings to Prelude over 25 years of pharmaceutical and biotech experience, most recently serving as President and Chief Executive Officer of Principia Biopharma until its acquisition by Sanofi S.A. in October 2020. Mr. Babler will serve as a member of the Audit Committee of the Board. "We are delighted to welcome Martin, a deeply experienced industry leader, to the Prelude Therapeutics Board of Directors," said Kris Vaddi, PhD, Chief Executive Officer. "We look forward